Chimerix, Inc. (CMRX) announced that the results of its phase II study, CMX001-201, on pipeline candidate CMX001 (brincidofovir) were published in New England Journal of Medicine.
We note that Chimerix is evaluating CMX001 for the prevention of cytomegalovirus (CMV) infection in recipients of hematopoietic cell transplant (HCT).
CMX001-201 was a randomized, placebo-controlled, double-blind, dose-escalation study conducted among 230 subjects.
The results from the study showed that it met its primary endpoint of reduction in CMV viremia and/or CMV disease with CMX001 100 mg administered twice weekly versus placebo.
We remind investors that earlier in the month Chimerix commenced a phase III trial (SUPPRESS) on CMX001, for the prevention of CMV infection in recipients of HCT. Data is expected in 2015.
Chimerix is also developing CMX001 as a medical countermeasure for combating smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA).
The other interesting candidiate in Chimerix’s portfolio is CMX157, an oral nucleotide analog lipid-conjugate for the treatment of HIV infection. The candidate was licensed to Merck & Co. Inc. (MRK) in Jul 2012.
We note that ViroPharma (VPHM) is also developing maribavir, for the treatment of CMV infections in transplant recipients.
ViroPharma received orphan drug designation in the EU for maribavir in Jun 2013 for the treatment of CMV in patients suffering from impaired cell mediated immunity. Maribavir was granted the same designation in the U.S. in May 2011 could not find the dates for the treatment of clinically significant CMV and disease in at-risk patients.
Chimerix currently carries a Zacks Rank #3 (Hold). Right now, companies that look attractive include Actelion Ltd. (ALIOF) and Affymetrix Inc. (AFFX). Both carry a Zacks Rank #1 (Strong Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment